IRIS
NAPOLITANO, Stefania
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
EU - Europa 3.317
AS - Asia 2.483
NA - Nord America 2.082
SA - Sud America 362
AF - Africa 33
OC - Oceania 3
Totale 8.280
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 2.032
RU - Federazione Russa 1.484
SG - Singapore 923
IE - Irlanda 598
IT - Italia 519
CN - Cina 516
HK - Hong Kong 485
BR - Brasile 314
DE - Germania 230
KR - Corea 182
GB - Regno Unito 129
VN - Vietnam 102
IN - India 81
JP - Giappone 65
UA - Ucraina 65
FR - Francia 61
SE - Svezia 45
FI - Finlandia 38
CA - Canada 31
GR - Grecia 31
TR - Turchia 28
PK - Pakistan 27
AT - Austria 25
NL - Olanda 19
AR - Argentina 18
CZ - Repubblica Ceca 17
BD - Bangladesh 15
BE - Belgio 14
PL - Polonia 14
ID - Indonesia 13
MX - Messico 13
ZA - Sudafrica 11
EC - Ecuador 9
AZ - Azerbaigian 8
ES - Italia 8
MA - Marocco 6
PY - Paraguay 6
IQ - Iraq 5
KE - Kenya 4
KG - Kirghizistan 4
UZ - Uzbekistan 4
VE - Venezuela 4
DO - Repubblica Dominicana 3
IL - Israele 3
KZ - Kazakistan 3
LT - Lituania 3
MK - Macedonia 3
PE - Perù 3
SA - Arabia Saudita 3
AE - Emirati Arabi Uniti 2
AU - Australia 2
BO - Bolivia 2
CH - Svizzera 2
CL - Cile 2
CO - Colombia 2
EG - Egitto 2
GI - Gibilterra 2
IR - Iran 2
JO - Giordania 2
LK - Sri Lanka 2
SN - Senegal 2
TH - Thailandia 2
TN - Tunisia 2
TW - Taiwan 2
UY - Uruguay 2
AL - Albania 1
AM - Armenia 1
AO - Angola 1
BA - Bosnia-Erzegovina 1
BG - Bulgaria 1
BW - Botswana 1
BY - Bielorussia 1
CG - Congo 1
CR - Costa Rica 1
DZ - Algeria 1
ET - Etiopia 1
GA - Gabon 1
GE - Georgia 1
HN - Honduras 1
HU - Ungheria 1
IS - Islanda 1
MD - Moldavia 1
NZ - Nuova Zelanda 1
PH - Filippine 1
PT - Portogallo 1
RO - Romania 1
SK - Slovacchia (Repubblica Slovacca) 1
SY - Repubblica araba siriana 1
TT - Trinidad e Tobago 1
Totale 8.280
Salva come PNG Salva come JPEG
Città #
Dublin 584
Hong Kong 483
Moscow 479
Singapore 434
Santa Clara 397
Chandler 282
Seoul 182
Naples 133
Hefei 109
Jacksonville 108
Dallas 99
Ashburn 90
New York 80
Beijing 78
Munich 69
Bremen 68
Princeton 66
Roxbury 66
Bengaluru 56
The Dalles 53
Caserta 43
Ho Chi Minh City 42
Los Angeles 38
Cambridge 37
Ann Arbor 33
Medford 29
São Paulo 29
Milan 22
Wilmington 20
Hanoi 19
Nuremberg 18
Brno 16
Elora 16
Boardman 14
Des Moines 14
Falkenstein 14
Napoli 13
Vienna 13
Brooklyn 12
Brussels 12
Warsaw 12
Woodbridge 12
Rome 11
San Francisco 11
Tokyo 11
Lappeenranta 10
Turku 10
Belo Horizonte 9
Houston 9
Istanbul 9
Rawalpindi 9
San Mateo 9
Baku 8
Ercolano 8
London 8
Rio de Janeiro 8
Shanghai 8
Amsterdam 7
Aversa 7
Columbus 7
Haiphong 7
Helsinki 7
Jinan 7
Tianjin 7
Dong Ket 6
Nanjing 6
Pozzuoli 6
Rimini 6
Toronto 6
Bahawalpur 5
Battipaglia 5
Brasília 5
Cape Town 5
Chennai 5
Chicago 5
Denver 5
Dhaka 5
Düsseldorf 5
Frosinone 5
Jakarta 5
Johannesburg 5
Manchester 5
Menlo Park 5
Mercato San Severino 5
Mountain View 5
Anantapur 4
Atlanta 4
Bari 4
Bishkek 4
Bologna 4
Boston 4
Campinas 4
Castellammare di Stabia 4
Council Bluffs 4
Da Nang 4
Fairfield 4
Frankfurt am Main 4
Gravataí 4
Guangzhou 4
Hyderabad 4
Totale 4.751
Salva come PNG Salva come JPEG
Nome #
Beyond N staging in colorectal cancer: Current approaches and future perspectives 145
EPHA2 is a predictive biomarker of resistance and a potential therapeutic target for improving anti-epidermal growth factor receptor therapy in colorectal cancer 137
Primary and Acquired Resistance of Colorectal Cancer to Anti-EGFR Monoclonal Antibody Can Be Overcome by Combined Treatment of Regorafenib with Cetuximab. 126
AXL is an oncotarget in human colorectal cancer 126
A case report of a severe fluoropyrimidine-related toxicity due to an uncommon DPYD variant 119
Eighth American Joint Committee on Cancer (AJCC) melanoma classification: what about stage IIC? 116
Clinical practice use of liquid biopsy to identify RAS/BRAF mutations in patients with metastatic colorectal cancer (mCRC): A single institution experience 113
Molecular aspects of resistance to biological and non-biological drugs and strategies to overcome resistance in colorectal cancer. 111
Comprehensive genome profiling by next generation sequencing of circulating tumor DNA in solid tumors: a single academic institution experience 111
Anti-tumor activity of cetuximab plus avelumab in non-small cell lung cancer patients involves innate immunity activation: findings from the CAVE-Lung trial 108
Clinical outcome and molecular characterisation of chemorefractory metastatic colorectal cancer patients with long-term efficacy of regorafenib treatment 107
Primary and Acquired Resistance of Colorectal Cancer Cells to Anti-EGFR Antibodies Converge on MEK/ERK Pathway Activation and Can Be Overcome by Combined MEK/EGFR Inhibition. 106
Liquid Biopsy at Home: Delivering Precision Medicine for Patients with Cancer During the Covid-19 Pandemic 101
Clinical outcome of patients with chemorefractory metastatic colorectal cancer treated with trifluridine/tipiracil (TAS-102): a single Italian institution compassionate use programme 100
Immunotherapy for head and neck cancer: Present and future 100
Clinical Utility of Liquid Biopsy to Detect BRAF and NRAS Mutations in Stage III/IV Melanoma Patients by Using Real-Time PCR 96
Antitumor efficacy of triple monoclonal antibody inhibition of epidermal growth factor receptor (EGFR) with MM151 in EGFRdependent and in cetuximab-resistant human colorectal cancer cells 96
Mixed Neuroendocrine Non-Neuroendocrine Neoplasms of the Gastrointestinal Tract: A Case Series 96
Clinical management of metastatic colorectal cancer in the era of precision medicine 95
CAVE-2 (Cetuximab-AVElumab) mCRC: A Phase II Randomized Clinical Study of the Combination of Avelumab Plus Cetuximab as a Rechallenge Strategy in Pre-Treated RAS/BRAF Wild-Type mCRC Patients 94
Gut microbiota correlates with antitumor activity in patients with mCRC and NSCLC treated with cetuximab plus avelumab 94
Biomarker-guided anti-egfr rechallenge therapy in metastatic colorectal cancer 93
Cetuximab rechallenge plus avelumab in pretreated patients with RAS Wild-type Metastatic Colorectal Cancer: The Phase 2 Single-Arm Clinical CAVE Trial 93
Baseline IFN-γ and IL-10 expression in PBMCs could predict response to PD-1 checkpoint inhibitors in advanced melanoma patients 92
Pretreatment Plasma Circulating Tumor DNA RAS/BRAF Mutational Status in Refractory Metastatic Colorectal Cancer Patients Who Are Candidates for Anti-EGFR Rechallenge Therapy: A Pooled Analysis of the CAVE and VELO Clinical Trials 91
Increased TGF-α as a mechanism of acquired resistance to the anti-EGFR inhibitor cetuximab through EGFR-MET interaction and activation of MET signaling in colon cancer cells 91
Atypical haemolytic-uraemic syndrome in patient with metastatic colorectal cancer treated with fluorouracil and oxaliplatin: A case report and a review of literature 91
Optimal treatment strategy for metastatic melanoma patients harboring BRAF-V600 mutations 91
Dramatic Therapeutic Response to Dabrafenib Plus Trametinib in BRAF V600E Mutated Papillary Craniopharyngiomas: A Case Report and Literature Review 91
Real-world clinical outcome and safety of adjuvant therapy in stage III melanoma patients: Data from two Academic Italian Institutions 90
Multiple Acquired Mutations Captured by Liquid Biopsy in the EGFR Addicted Metastatic Colorectal Cancer 89
Anti-EGFR-resistant clones decay exponentially after progression: Implications for anti-EGFR re-challenge 89
Which treatment after first line therapy in NSCLC patients without genetic alterations in the era of immunotherapy? 88
Regorafenib in combination with silybin as a novel potential strategy for the treatment of metastatic colorectal cancer 87
Multi-Omic Approaches in Colorectal Cancer beyond Genomic Data 87
Antitumor efficacy of dual blockade with encorafenib plus cetuximab in combination with chemotherapy in human BRAFV600E mutant colorectal cancer 86
Real-World Activity and Safety of Trifluridine-Tipiracil Plus Bevacizumab Therapy in Patients with Refractory Metastatic Colorectal Cancer 85
How immunotherapy has changed the continuum of care in hepatocellular carcinoma 85
Genetic Landascape of Primary versus metastatic colorectal cancer: to what extent are they concordant ? 84
Mechanisms of resistance to anti-epidermal growth factor receptor inhibitors in metastatic colorectal cancer 83
Dual inhibition of TGFβ and AXL as a novel therapy for human colorectal adenocarcinoma with mesenchymal phenotype 83
Clinical efficacy of sequential treatments in KRASG12C-mutant metastatic colorectal cancer: findings from a real-life multicenter Italian study (CRC-KR GOIM) 82
"RT STRIKES BACK": Radiotherapy in Ultra Elderly with Cutaneous Basal Cell Carcinoma 82
Present and future of metastatic colorectal cancer treatment: A review of new candidate targets 82
Immunotherapy in colorectal cancer: is the long-awaited revolution finally happening? 82
Comprehensive Review on the Clinical Relevance of Long Non-Coding RNAs in Cutaneous Melanoma 82
MET ACTIVATION BY AUTOCRINE LOOP RESCUES COLON CANCER CELLS FROM SENSITIVITY TO EGFR INHIBITION 81
PRAME Immunocytochemistry for the Diagnosis of Melanoma Metastases in Cytological Samples 81
Vulnerability to low-dose combination of irinotecan and niraparib in ATM-mutated colorectal cancer 80
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 79
Panitumumab Plus Trifluridine-Tipiracil as Anti-Epidermal Growth Factor Receptor Rechallenge Therapy for Refractory RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial 79
It is finally time for adjuvant therapy in melanoma 78
Post-Irradiation Breast Angiosarcoma: All the Possible Treatments and Electrochemotherapy. Case Report and Literature Review 77
Maintenance Treatment with Cetuximab and BAY86-9766 Increases Antitumor Efficacy of Irinotecan plus Cetuximab in Human Colorectal Cancer Xenograft Models 77
DNA-PK inhibition sustains the antitumor innate immune response in small cell lung cancer 76
Establishment of patient-derived tumor organoids to functionally inform treatment decisions in metastatic colorectal cancer 76
Comprehensive genomic profiling by liquid biopsy captures tumor heterogeneity and identifies cancer vulnerabilities in patients with RAS/BRAF wild-type metastatic colorectal cancer in the CAPRI 2-GOIM trial 76
Radiomic Parameters for the Evaluation of Response to Treatment in Metastatic Colorectal Cancer Patients with Liver Metastasis: Findings from the CAVE-GOIM mCRC Phase 2 Trial 75
Management of Non-Melanoma Skin Cancer: Radiologists Challenging and Risk Assessment 74
ITGB1 and DDR activation as novel mediators in acquired resistance to osimertinib and MEK inhibitors in EGFR-mutant NSCLC 74
The Role of Adjuvant Therapy for the Treatment of Micrometastases in Endometrial Cancer: A Systematic Review and Meta-Analysis 73
Therapeutic value of EGFR inhibition in CRC and NSCLC: 15 years of clinical evidence. 73
Therapeutic efficacy of SYM004, a mixture of two anti-EGFR antibodies in human colorectal cancer with acquired resistance to cetuximab and MET activation 73
Treatment of cutaneous melanoma harboring smo p.Gln216arg mutation with imiquimod: An old drug with new results 73
Impact of a cardio-oncology unit on prevention of cardiovascular events in cancer patients 73
Triple blockade of Ido-1, PD-L1 and MEK as a potential therapeutic strategy in NSCLC 72
The Role of Sentinel Node Biopsy in the Era of Adjuvant Therapy for Melanoma 72
Resistance to anti-epidermal growth factor receptor in metastatic colorectal cancer: What does still need to be addressed? 71
Pimasertib hydrochloride 71
NMR profiling of Ononis diffusa identifies cytotoxic compounds against cetuximab-resistant colon cancer cell lines 70
How we treat metastatic colorectal cancer 69
Current Landscape and Open Questions on Adjuvant Therapies in Melanoma 69
Previous radiotherapy increases the efficacy of cemiplimab in the treatment of locally advanced and metastatic cutaneous squamous cell carcinoma: A retrospective analysis 68
Skin toxicity as predictor of survival in refractory patients with ras wild‐type metastatic colorectal cancer treated with cetuximab and avelumab (Cave) as rechallenge strategy 68
Receptor tyrosine kinase-dependent PI3K activation is an escape mechanism to vertical suppression of the EGFR/RAS/MAPK pathway in KRAS-mutated human colorectal cancer cell lines 67
A retrospective observational study on cutaneous adverse events induced by immune checkpoint inhibitors 66
Retrospective Study of Regorafenib Versus TAS-102 Efficacy and Safety in Chemorefractory Metastatic Colorectal Cancer (mCRC) Patients: A Multi-institution Real Life Clinical Data 66
Cetuximab as third-line rechallenge plus either irinotecan or avelumab is an effective treatment in metastatic colorectal cancer patients with baseline plasma RAS/BRAF wild-type circulating tumor DNA: Individual patient data pooled analysis of CRICKET and CAVE trials 66
Now or Later? The Role of Neoadjuvant Treatment in Advanced Endometrial Cancer: A Systematic Review 64
Feasibility of next-generation sequencing in clinical practice: Results of a pilot study in the Department of Precision Medicine at the University of Campania ' Luigi Vanvitelli' 63
Correction: Ciardiello et al. Biomarker-Guided Anti-EGFR Rechallenge Therapy in Metastatic Colorectal Cancer. Cancers 2021, 13, 1941 63
Efficacy and safety of a biomarker-driven cetuximab-based treatment regimen over 3 treatment lines in mCRC patients with RAS/BRAF wild type tumors at start of first line: The CAPRI 2 GOIM trial 62
Novel in vitro cancer models for optimizing anti- EGFR therapies 62
Resistance Mechanisms to Anti-Epidermal Growth Factor Receptor Therapy in RAS/RAF Wild-Type Colorectal Cancer Vary by Regimen and Line of Therapy 61
Predictive Evaluation on Cytological Sample of Metastatic Melanoma: The Role of BRAF Immunocytochemistry in the Molecular Era 61
Triple blockade of EGFR, MEK and PD-L1 has antitumor activity in colorectal cancer models with constitutive activation of MAPK signaling and PD-L1 overexpression 60
PBMCs as Tool for Identification of Novel Immunotherapy Biomarkers in Lung Cancer 60
Prevention of cardiovascular complications in elderly cancer patients 59
Combined blockade of MEK and PI3KCA as an effective antitumor strategy in HER2 gene amplified human colorectal cancer models 57
Anti-EGFR Rechallenge in Patients With Refractory ctDNA RAS/BRAF wt Metastatic Colorectal Cancer 56
Overexpression of CCL-20 and CXCL-8 genes enhances tumor escape and resistance to cemiplimab, a programmed cell death protein-1 (PD-1) inhibitor, in patients with locally advanced and metastatic cutaneous squamous cell carcinoma 56
Mechanisms of innate and acquired resistance to anti-EGFR therapy: A review of current knowledge with a focus on rechallenge therapies 55
MicroRNA Expression in Endometrial Cancer: Current Knowledge and Therapeutic Implications 54
Towards the era of precision medicine in metastatic colorectal cancer 54
Panitumumab plus trifluridine/tipiracil as anti‐EGFR rechallenge therapy in patients with refractory RAS wild‐type metastatic colorectal cancer: Overall survival and subgroup analysis of the randomized phase II VELO trial 53
Sentinel node biopsy in thin melanoma: a retrospective descriptive cohort study 52
Final results of the CAVE trial in RAS wild type metastatic colorectal cancer patients treated with cetuximab plus avelumab as rechallenge therapy: Neutrophil to lymphocyte ratio predicts survival. 52
Evolving Strategies for the Management of BRAF-Mutant Metastatic Colorectal Cancer 52
Diagnostic value of liquid biopsy in the era of precision medicine: 10 years of clinical evidence in cancer 51
How we treat locoregional melanoma 50
Totale 8.076
Salva come PNG Salva come JPEG
Categoria #
all - tutte 35.973
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 35.973
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2020/2021156 0 0 0 0 0 13 25 23 12 29 38 16
2021/2022514 15 13 6 4 105 15 38 15 30 59 64 150
2022/20231.193 127 18 32 96 149 97 5 66 545 9 33 16
2023/2024596 61 25 17 23 158 88 18 22 18 14 54 98
2024/20252.156 52 53 30 98 295 295 277 221 265 242 182 146
2025/20263.434 382 448 431 353 743 1.077 0 0 0 0 0 0
Totale 8.528